Role of Rebiopsy in Relapsed Non-Small Cell Lung Cancer for Directing Oncology Treatments

Table 6

Recommendation for rebiopsy in NSCLC.

When rebiopsy should not be performed:
(i) Too difficult a location for safe biopsy
(ii) Result will not change treatment
When rebiopsy should be performed:
(i) If the prior specimen is too small for adequate tumor characterization, including genetic testing for predictive alterations
(ii) If relapse happens a long time (six months) after CR treatment result
(iii) If the new tumor behaves in a different way than expected from the primary tumor
(iv) If new molecules entering clinical trials in the near future is foreseeable, such as adenocancer relapses